Business Context and Reporting Period
This Form 6-K filing by Immunocore Holdings Plc reports on the Annual General Meeting (AGM) held on May 16, 2023. The filing serves to disclose the voting results of resolutions proposed to shareholders, including the adoption of accounts for the financial year ended December 31, 2022, and the re-election of directors.
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. It references the adoption of the UK Annual Report for the year ended December 31, 2022, but does not include the numerical data from that report within this document.
Material Changes
No material financial changes or operational updates are detailed in this filing. The document focuses exclusively on the procedural outcomes of the AGM resolutions.
Guidance, Outlook, and Management Commentary
There is no forward-looking guidance, management commentary on future outlook, or discussion of risks and contingencies in this specific filing. The content is limited to the confirmation that all resolutions were passed on a poll, following the board's recommendations.
Key Facts for Investor Verification
- AGM Date: May 16, 2023.
- Resolution Outcomes: All eight resolutions were passed, including the adoption of 2022 accounts and the re-election of directors Robert Perez, Kristine Peterson, and Siddharth Kaul.
- Shareholder Dissent: Resolution 2 (Directors' remuneration report) received the highest opposition, with 21.51% of votes cast against it.
- Auditor Appointment: Deloitte LLP was re-appointed as the Company's auditor.
- Financial Data Source: Detailed financial metrics for 2022 are not in this filing; investors must refer to the UK Annual Report available on the company's investor relations website.